FDA Clears Organogenesis' Next Generation PuraPly Surgical Solution

by Vandana Singh, Benzinga Editor

August 15, 2022 1:06 PM | 1 min read |

Organogenesis Holdings Inc ORGO has received the FDA 510k Clearance for PuraPly MZ, a brand extension to the PuraPly product portfolio.
Of the U.S.'s 40 to 50 million surgeries each year, up to 28% of surgical sites must be left open to heal.
Related: Organogenesis' Q2 Operating Income Fell 50%, Lowers Annual Guidance.
Organogenesis developed PuraPly MZ, a powder designed to support wound healing in deep, tunneling, and complex wounds to support clinicians and patients with these complex post-surgical wounds.
PuraPly MZ consists of native structured collagen designed to allow for maximum coverage and maintenance of optimal contact with the contours of the wound surface to support healing.
Price Action: ORGO shares are up 2.44% at $4.83 during the market session on the last check Monday.

Posted In: News Penny Stocks Health Care Small Cap FDA General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.